Mallinckrodt, an Ireland-based global specialty pharmaceutical company, has completed the sale of its previously announced Therakos business to CVC Capital Partners Fund IX for a purchase price of US$925m. Therakos is provides Extracorporeal…
Ireland: CVC completes acquisition of Therakos from Mallinckrodt
…
…






